$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
索拉非尼延长转移性甲状腺癌患者生存期
2025-10-19 11:44:20
Check Details
乐伐替尼治疗分化型甲状腺癌安全有效
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌客观缓解率为65%
2025-10-19 11:44:20
Check Details
仑伐替尼治疗分化型甲状腺癌的效果
2025-10-19 11:44:20
Check Details
乐伐替尼治疗老年分化型甲状腺癌患者
2025-10-19 11:44:20
Check Details
乐伐替尼治疗分化型甲状腺癌的临床数据
2025-10-19 11:44:20
Check Details
乐伐替尼延长分化型甲状腺癌患者的生存期
2025-10-19 11:44:20
Check Details
卡博替尼在肝细胞癌中的应用:2期安慰剂对照研究结果
2025-10-19 11:44:20
Check Details
仑伐替尼治疗甲状腺癌
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌有效率
2025-10-19 11:44:20
Check Details
乐伐替尼治疗放射性碘治疗失败分化型甲状腺癌
2025-10-19 11:44:20
Check Details
卡博替尼治疗甲状腺髓样癌
2025-10-19 11:44:20
Check Details
1
2
...
8517
8518
8519
8520
8521
8522
8523
...
10234
10235
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lemborexant for Insomnia: Dual Orexin 5/10mg, 7-Hour Bedtime, 7–10-Day Review and Safety
2
Fayuvi (rebisufligene etisparvovec-hopf) for MPS IIIA: AAV9 Single Infusion, Weight-Based Dose, Steroids, Liver/Platelet Monitoring
3
Trelagliptin Once-Weekly DPP-4 for Type 2 Diabetes: Dosing, Renal Adjustment, Discontinuation
4
Orforglipron (Foundayo) vs Metformin: Oral GLP-1 Weight Loss and T2D Use
5
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
6
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS
7
Finerenone (Kerendia) for Diabetic CKD and HF with LVEF≥40%: Albuminuria, Dosing, Hyperkalemia
8
Baxdrostat (Baxfendy) for Hypertension: Aldosterone Synthase Inhibition, Dosing, and Discontinuation Rules
9
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
10
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
11
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
12
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring